glp 1 or tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are FDA Says Shortage of GLP-1

Higher-dose formulations approved for weight management produce more substantial losses: semaglutide 2.4 mg (Wegovy) typically achieves 15-17% of baseline body weight loss, while liraglutide 3.0 mg (Saxenda) averages 5-7%

The heart, in particular, depends on a continuous and substantial supply of ATP to maintain its function, which is why CoQ10 has been one of the most studied supplements in the context of cardiovascular support.*

Body Lift For patients who have lost a massive amount of weight (often 75+ pounds), a lower body lift may be necessary

Michigan cuts off weight-loss drugs for most Medicaid patients, saving $240 million

I dose both blends subcutaneously, in the abdomen or thigh, once daily for the first three to four weeks after surgery

She maintained the use of compression garments throughout her therapy, which supported circulation and helped optimize results